Materias dentro de su búsqueda.
Mostrando 84,261 - 84,280 Resultados de 84,353 Para Buscar '"HR"', tiempo de consulta: 0.73s Limitar resultados
  1. 84261
    “…Her blood test results showed mild increase in platelets (476 * 109), CRP 8mg/L, ESR (18mm/hr). IgG4 titres were mildly raised (1.16g/L). Other immunologic markers including rheumatoid factor, human leukocyte antigen B27, antinuclear antibody and anti-neutrophil cytoplasmic antibody were normal. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P43 A complicated road to diagnosis: Auto inflammatory bone disease
  2. 84262
    “…Molnupiravir use was associated with lower risks of death (HR 0·76 [95% CI 0·61–0·95]) and in-hospital disease progression (0·57 [0·43–0·76]) than non-use was, whereas risk of hospitalisation was similar in both groups (0·98 [0·89–1·06]). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
  3. 84263
    “…Over 4·2 years median follow-up (IQR 3·0–5·0), a 5 mm Hg reduction in systolic blood pressure decreased the risk of major cardiovascular events in both groups, but with a weaker relative treatment effect in participants with type 2 diabetes (HR 0·94 [95% CI 0·91–0·98]) compared with those without type 2 diabetes (0·89 [0·87–0·92]; p(interaction)=0·0013). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
  4. 84264
    “…Abdomen 40". TA120 / 80. RR16 p.m. HR72 p.m. BLOOD HORMONE TEST: IGF-1 230 ng / mL (NV: 64.0-218 ng / mL). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PMON121 GALACTORRHEA, MACROPROLACTINOMA IN A 53-YEAR-OLD MALE
  5. 84265
    “…After accounting for gender, race, payer, age, high-risk behavior, F/TDF had a higher risk of discontinuation or switch (HR=4.9 CI 3.9-6.2); Black race was also associated with higher risk of discontinuation or switch [Table 2]. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2087. Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among PrEP-Naive (PN) Individuals After F/TAF Approval in the United States (US)
  6. 84266
    “…Patients admitted with a primary diagnosis of AF satisfying the AF virtual ward (AFVW) entry criteria (i.e., haemodynamically stable, HR <140 bpm with other acute conditions excluded) were given access to a single lead ECG recording device, a Bluetooth integrated blood pressure machine and pulse oximeter with instruction to record daily ECGs, blood pressure readings, oxygen saturations and fill an online AF symptom questionnaire via a smart phone or electronic tablet. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Atrial fibrillation virtual ward: reshaping the future of AF care
  7. 84267
    “…Among the categorized groups, prognosis values of sTPC and mTPC2 groups were not statically different from that of the matched single lung cancer, whereas increased overall survival time and decreased incidence of all-cause and cancer-specific death relative to the matched patients were observed in mTPC1 group (H.R 0.28, 95% CI 0.19–0.41; SHR 0.33, 95% CI 0.23–0.47). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognosis of male lung cancer patients with urinary cancer: a study from a national population-based analysis
  8. 84268
    “…Of these, 211 were randomised and 207 were included in the final analysis (n=67 in the combination group, n=71 in the infliximab withdrawal group, and n=69 in the immunosuppressant withdrawal group). 39 patients had a relapse (eight [12%] of 67 in the combination group, 25 [35%] of 71 in the infliximab withdrawal group, six [9%] of 69 in the immunosuppressant withdrawal group). 2-year relapse rates were 14% (95% CI 4–23) in the combination group, 36% (24–47) in the infliximab withdrawal group, and 10% (2–18) in the immunosuppressant withdrawal group (hazard ratio [HR] 3·45 [95% CI 1·56–7·69], p=0·003, for infliximab withdrawal vs combination, and 4·76 [1·92–11·11], p=0·0004, for infliximab withdrawal vs immunosuppressant withdrawal). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
  9. 84269
    “…The PS weighted incidence of hospitalisation for COVID-19 was also lower in the BNT162b2 vaccine group than that in the ChAdOx1 vaccine group (RD: -0.09, 95%CI: -0.13 to -0.05 per 1000 person-months; HR: 0.65, 95%CI: 0.57 to 0.74). No significant difference in the risk of death from COVID-19 was observed between the two comparison groups. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
  10. 84270
    “…Bacteria (1 x 10(6) CFU/mL) were exposed to sulopenem concentrations that mimicked human free-drug plasma concentration-time profiles (protein binding of 10.7%, T(max) = 2 hr and a t(1/2) of 1.18 hr) following oral drug administration. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
  11. 84271
    Publicado 2007
    Tabla de Contenidos: “…Virtual room concepts for cooperative, scientific work -- Comparative study of learning achievement on the online asynchronous learning course in engineering metallurgy between individual-learning and group-learning -- An architecture for a SCORM-conformant content delivery system in an e-learning solution -- Impact of university education on software quality skill-set of HR in software outsourcing industry of Pakistan -- State model diagrams : a systems tool for teaching network technologies and network management -- Cooperative learning objects in a federated learning system -- Application of meet-distributive lattices for assessing students knowledge -- The concept of the internet textbook on theoretical mechanics -- Game playing and systems thinking -- Research on maintainability and expansibility of e-learning systems -- Research on web-based self-learning -- Design and development of an e-learning tool for children to learn how to write the Chinese words -- A study support system on a hands-on networking laboratory -- User modeling in the context of cognitive service delivery : application to learning management systems -- Management architecture for the provision of e-services in cognitive environments -- E-learning techniques in IT programs -- E-learning based distance education at Szechenyi Istvan University -- The web enhanced general physics course -- Accessibility and model-based web application development for e-learning environments -- Creation of a teaching timetable using random variables : the STB application -- E-learning and handicap : new trends for accessibility with model driven approach -- Two different approaches of modeling the teacher relocation problem in a constraint logic programming system and their comparison -- A continuous unsupervised adaptation method for speaker verification.…”
    Tabla de contenido
    Procedimiento de la Conferencia Libro
    Innovations in e-learning, instruction technology, assessment, and engineering education /
  12. 84272
    por CERN. Geneva
    Publicado 2022
    “…</p> <p>En français avec interprétation simultanée en anglais<br /> Places limitées, <a href="https://indico.cern.ch/event/1153654/registrations/82649/">inscription obligatoire&nbsp;</a><br /> Suivez la&nbsp;<a href="https://webcast.web.cern.ch/event/i1153654">Retransmission en ligne</a> en direct</p> <table border="0" cellpadding="1" cellspacing="1" style="width:650px"> <tbody> <tr> <td><img alt="" src="https://indico.cern.ch/event/1153654/images/36402-GFC%20.jpg" style="height:107px; width:200px" /></td> <td>Conférence organisée à l'initiative du Groupement des Français du CERN (GFC)</td> </tr> </tbody> </table> <hr /> <h3><em>A conference by Jean Jouzel<br /> Climatologist, Emeritus Research Director at the CEA, former Vice-President of Group I of the IPCC (Intergovernmental Panel on Climate Change)</em></h3> <p><em>If nothing were done to reduce our greenhouse gas emissions, by 2100 we would be heading towards an average warming of between 4 and 5°C, or even more, while the commitments made within the framework of the Paris agreement puts us, by this deadline, on a trajectory of warming above 3°C. …”
    Enlace del recurso
    Conférence de Jean Jouzel : l'urgence climatique | The climate emergency
  13. 84273
    “…PFS at 2 years was 84.2% (95% CI 76.4–92.8) in arm A and 78.4% (95% CI 69.5–88.3) in arm B (HR 1.39, 95% CI 0.69–2.79, p = 0.40). At the time of analysis, there were 26 disease failures, 9 in arm A and 17 in arm B. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Radiotherapy—Dose Escalated for Large Volume Primary Tumors—And Cetuximab with or without Induction Chemotherapy for HPV Associated Squamous Cell Carcinoma of the Head and Neck—A Randomized Phase II Trial
  14. 84274
    “…id=73862&v=1.5&u_atoken=b403af53-d3b9-41ae-a7e2-db5498609b0c&u_asession=01tNh69p235bMUO4CmHIXcv8Hxirl5-557Duue9QB5lGfl3mf8IvPlcs2kN2zC30voX0KNBwm7Lovlpxjd_P_q4JsKWYrT3W_NKPr8w6oU7K_AyPrQhedMUWBMR2-ZDL_KO0uwDPR9XlF566xraDvT9mBkFo3NEHBv0PZUm6pbxQU&u_asig=05Kd_Q8fjv-24MVbZpOS9ef3xuCCN-tSVH5eUoJKgNLM7E0-n0zMpW6xLq9gh9aUhkKEEA15rdDoCydncF99APBwVSaTPgEG_V_B1iT4wimdCTxV_4ZVbTlDewxyQtE4YgU4-Oza7KPi94RJ64Utel0yZfqg3Tlm-bVxFNOY-zXFP9JS7q8ZD7Xtz2Ly-b0kmuyAKRFSVJkkdwVUnyHAIJzSYJ6SfhFl0WMTCCasZ7zV2I2qfyrp5m-SELPVeREKgX_6yRmLu26qT8kGfcS-Yaeu3h9VXwMyh6PgyDIVSG1W-7D_Sko5YQtpDbs3uvezYkZcUUY4o9-zDPaoYelmMDs8u7I4TPvtCXaPp44YUJcQ9bHr-_RmKA5V8nji3daArhmWspDxyAEEo4kbsryBKb9Q&u_aref=NNH1nHSUCE6pNvCilV%2F1MD0aERs%3D), identifier (ChiCTR2000039327).…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Predictive factors and clinical efficacy of Chinese medicine Shengji ointment in the treatment of diabetic foot ulcers in the elderly: a prospective study
  15. 84275
    “…Her CRP was 99mg/L, ESR 55 mm/hr, with ferritin at 274 ug/L. She has mildly deranged LFTs (ALT of 55 U/L, ALP 498 U/L). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P21 Lupus or else?
  16. 84276
    “…[Figure: see text] RESULTS: Kaplan-Meier estimates showed a 28-Day mortality rate of 31.7% for Vilo vs 41.6% for Plc [HR 0.67 (95% CI: 0.48, 0.96), p< 0.05] with similar 60-Day results. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    87. The safety and efficacy advantage of blocking C5a vs C5 in critically ill, COVID-19 patients: Results from PANAMO, a Phase 3 randomized controlled trial
  17. 84277
    “…PK parameters were determined by non-compartmental analysis (5 samples over 24 hr, 38/63 pts). Safety was assessed by evaluation of adverse events. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study
  18. 84278
    “…RESULTS: Key recommendations, listed by category, include: early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1C); blood cultures prior to antibiotic therapy (1C); imaging studies performed promptly to confirm potential source of infection (1C); administration of broad-spectrum antibiotic therapy within 1 hr of diagnosis of septic shock (1B) and severe sepsis without septic shock (1D); reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7–10 days of antibiotic therapy guided by clinical response (1D); source control with attention to the balance of risks and benefits of the chosen method (1C); administration of either crystalloid or colloid fluid resuscitation (1B); fluid challenge to restore mean circulating filling pressure (1C); reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (1D); vasopressor preference for norepinephrine or dopamine to maintain an initial target of mean arterial pressure ≥ 65 mm Hg (1C); dobutamine inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1C); stress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); recombinant activated protein C in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for post-operative patients). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
  19. 84279
    por Garcia-Closas, Montserrat, Hall, Per, Nevanlinna, Heli, Pooley, Karen, Morrison, Jonathan, Richesson, Douglas A., Bojesen, Stig E., Nordestgaard, Børge G., Axelsson, Christen K., Arias, Jose I., Milne, Roger L., Ribas, Gloria, González-Neira, Anna, Benítez, Javier, Zamora, Pilar, Brauch, Hiltrud, Justenhoven, Christina, Hamann, Ute, Ko, Yon-Dschun, Bruening, Thomas, Haas, Susanne, Dörk, Thilo, Schürmann, Peter, Hillemanns, Peter, Bogdanova, Natalia, Bremer, Michael, Karstens, Johann Hinrich, Fagerholm, Rainer, Aaltonen, Kirsimari, Aittomäki, Kristiina, von Smitten, Karl, Blomqvist, Carl, Mannermaa, Arto, Uusitupa, Matti, Eskelinen, Matti, Tengström, Maria, Kosma, Veli-Matti, Kataja, Vesa, Chenevix-Trench, Georgia, Spurdle, Amanda B., Beesley, Jonathan, Chen, Xiaoqing, Australian Ovarian Cancer Management Group, The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Devilee, Peter, van Asperen, Christi J., Jacobi, Catharina E., Tollenaar, Rob A. E. M., Huijts, Petra E.A., Klijn, Jan G. M., Chang-Claude, Jenny, Kropp, Silke, Slanger, Tracy, Flesch-Janys, Dieter, Mutschelknauss, Elke, Salazar, Ramona, Wang-Gohrke, Shan, Couch, Fergus, Goode, Ellen L., Olson, Janet E., Vachon, Celine, Fredericksen, Zachary S., Giles, Graham G., Baglietto, Laura, Severi, Gianluca, Hopper, John L., English, Dallas R., Southey, Melissa C., Haiman, Christopher A., Henderson, Brian E., Kolonel, Laurence N., Le Marchand, Loic, Stram, Daniel O., Hunter, David J., Hankinson, Susan E., Cox, David G., Tamimi, Rulla, Kraft, Peter, Sherman, Mark E., Chanock, Stephen J., Lissowska, Jolanta, Brinton, Louise A., Peplonska, Beata, Klijn, Jan G. M., Hooning, Maartje J., Meijers-Heijboer, Han, Collee, J. Margriet, van den Ouweland, Ans, Uitterlinden, Andre G., Liu, Jianjun, Lin, Low Yen, Yuqing, Li, Humphreys, Keith, Czene, Kamila, Cox, Angela, Balasubramanian, Sabapathy P., Cross, Simon S., Reed, Malcolm W. R., Blows, Fiona, Driver, Kristy, Dunning, Alison, Tyrer, Jonathan, Ponder, Bruce A. J., Sangrajrang, Suleeporn, Brennan, Paul, McKay, James, Odefrey, Fabrice, Gabrieau, Valerie, Sigurdson, Alice, Doody, Michele, Struewing, Jeffrey P., Alexander, Bruce, Easton, Douglas F., Pharoah, Paul D.
    Publicado 2008
    “…Three SNPs (rs2981582, rs3803662, and rs889312) showed weak but significant associations with ER-negative disease, the strongest association being for rs3803662 in TNRC9 (1.14 (1.09–1.21)). rs13281615 in 8q24 was associated with an improvement in survival after diagnosis (per-allele HR = 0.90 (0.83–0.97). The association was attenuated and non-significant after adjusting for known prognostic factors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics
  20. 84280
    por Gaudet, Mia M., Kuchenbaecker, Karoline B., Vijai, Joseph, Klein, Robert J., Kirchhoff, Tomas, McGuffog, Lesley, Barrowdale, Daniel, Dunning, Alison M., Lee, Andrew, Dennis, Joe, Healey, Sue, Dicks, Ed, Soucy, Penny, Sinilnikova, Olga M., Pankratz, Vernon S., Wang, Xianshu, Eldridge, Ronald C., Tessier, Daniel C., Vincent, Daniel, Bacot, Francois, Hogervorst, Frans B. L., Peock, Susan, Stoppa-Lyonnet, Dominique, Peterlongo, Paolo, Schmutzler, Rita K., Nathanson, Katherine L., Piedmonte, Marion, Singer, Christian F., Thomassen, Mads, Hansen, Thomas v. O., Neuhausen, Susan L., Blanco, Ignacio, Greene, Mark H., Garber, Judith, Weitzel, Jeffrey N., Andrulis, Irene L., Goldgar, David E., D'Andrea, Emma, Caldes, Trinidad, Nevanlinna, Heli, Osorio, Ana, van Rensburg, Elizabeth J., Arason, Adalgeir, Rennert, Gad, van den Ouweland, Ans M. W., van der Hout, Annemarie H., Kets, Carolien M., Aalfs, Cora M., Wijnen, Juul T., Ausems, Margreet G. E. M., Frost, Debra, Ellis, Steve, Fineberg, Elena, Platte, Radka, Evans, D. Gareth, Jacobs, Chris, Adlard, Julian, Tischkowitz, Marc, Porteous, Mary E., Damiola, Francesca, Golmard, Lisa, Barjhoux, Laure, Longy, Michel, Belotti, Muriel, Ferrer, Sandra Fert, Mazoyer, Sylvie, Spurdle, Amanda B., Manoukian, Siranoush, Barile, Monica, Genuardi, Maurizio, Arnold, Norbert, Meindl, Alfons, Sutter, Christian, Wappenschmidt, Barbara, Domchek, Susan M., Pfeiler, Georg, Friedman, Eitan, Jensen, Uffe Birk, Robson, Mark, Shah, Sohela, Lazaro, Conxi, Mai, Phuong L., Benitez, Javier, Southey, Melissa C., Schmidt, Marjanka K., Fasching, Peter A., Peto, Julian, Humphreys, Manjeet K., Wang, Qin, Michailidou, Kyriaki, Sawyer, Elinor J., Burwinkel, Barbara, Guénel, Pascal, Bojesen, Stig E., Milne, Roger L., Brenner, Hermann, Lochmann, Magdalena, Aittomäki, Kristiina, Dörk, Thilo, Margolin, Sara, Mannermaa, Arto, Lambrechts, Diether, Chang-Claude, Jenny, Radice, Paolo, Giles, Graham G., Haiman, Christopher A., Winqvist, Robert, Devillee, Peter, García-Closas, Montserrat, Schoof, Nils, Hooning, Maartje J., Cox, Angela, Pharoah, Paul D. P., Jakubowska, Anna, Orr, Nick, González-Neira, Anna, Pita, Guillermo, Alonso, M. Rosario, Hall, Per, Couch, Fergus J., Simard, Jacques, Altshuler, David, Easton, Douglas F., Chenevix-Trench, Georgia, Antoniou, Antonis C., Offit, Kenneth
    Publicado 2013
    “…We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80–0.90, P = 3.9×10(−8)). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk
Herramientas de búsqueda: RSS